Oncology

Data from the BEACON CRC trial show encorafenib, binimetinib, and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer.

Study finds elevated risk factors for cardiovascular disease in postmenopausal women with a history of breast cancer.

New study demonstrates a novel approach of linking HER2-targeting antibodies with chemotherapy drugs for patients with breast cancer.

Research adds to a previously found correlation between yogurt consumption and a lowered risk of bowel cancer.

There are currently an estimated 8.1 million males and 8.8 million females in the United States with a history of cancer.

A protein called DDX3X has been found to regulate a melanoma-specific oncogene called MITF that is central to the development of the pigment cells in the skin.

A recent study analyzed the 10-year absolute risks of thromboembolism and bleeding in patients with a history of hematologic cancer.

As young patients with bone cancer are often treated with high doses of chemotherapy before and after surgery, researchers wanted to develop gentler treatment options.

FOXA1 has been previously known to be mutated in prostate cancer; however, its biological functions were not understood well.

Certain HER2-positive breast cancers may benefit from anti-HER2 therapy alone without the need for chemotherapy.

Top news of the day from across the health care landscape.

Colon cancer may spread to other parts of the body before original tumors are clinically detectable.

Top news of the day from across the health care landscape.

Pembrolizumab is already an established treatment option for non-small cell lung cancer, with several approved indications for its use in the disease.

Racial, ethnic, and socioeconomic disparities in cancer survival rates continue to increase for adolescents and young adults.

Study findings suggest that triple-negative breast cancer incidence among black women is not generalizable to all women of African descent.

Officials with the FDA approved Amgen’s trastuzumab-anns, also known as ABP 980 (Kanjinti), the fifth FDA-approved biosimilar referencing trastuzumab (Herceptin).

Slow walking speed associated with higher risk of poor outcomes for older patients with blood cancers.

An unhealthy microbiome caused by chronic antibiotic treatment could result in long-term inflammation within the tissue and tumor environment.

Top news of the week from Specialty Pharmacy Times.

Breast cancers with somatic or germline BRCA 1/2 mutations may not be as responsive to checkpoint inhibitors as previously thought.

Top news of the day from across the health care landscape.

Ginah Nightingale, PharmD, BCOP, associate professor of pharmacy practice at the Jefferson College of Pharmacy at Thomas Jefferson University discusses how pharmacist-led interventions help to reduce adverse events associated with polypharmacy in geriatric patients during the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

Jorge Eduardo Cortes, MD, Deputy Chair and Professor of Medicine in the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas, references the ENESTop 192-week study results in which treatment-free remission was achieved in patients with chronic myeloid leukemia in chronic phase after stopping second-line nilotinib.

Ginah Nightingale, PharmD, BCOP, associate professor of pharmacy practice at the Jefferson College of Pharmacy at Jefferson University, discusses how pharmacists can counsel geriatric patients who may be taking multiple medications for chronic illnesses during the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

The Impassion130 trial evaluated whether atezolizumab plus nanoparticle albumin-bound paclitaxel increased overall survival in patients with triple negative breast cancer when compared to chemotherapy alone.

During the American Society of Clinical Oncology Annual Meeting in Chicago, IL, Ali McBride, PharmD, BCOP, president of the Association of Community Cancer Centers, discusses how growth in the oncology space will affect how pharmacists practice.